Aileron Therapeutics is a biopharmaceutical company that develops and commercializes stabilized cell-permeating alpha-helical peptides to address intracellular targets in oncology and other therapeutic areas. Co.'s product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53's interactions with its endogenous inhibitors, MDMX and MDM2. ALRN-6924 is designed to activate the mechanisms used by p53 in cells with non-mutant, or wild-type, p53 to regulate cell division and progression through the cell replication cycle, programmed death of cancerous cells, or apoptosis, and induction of the immune system to respond against cancer cells. The ALRN stock yearly return is shown above.
The yearly return on the ALRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|